Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cost of Revenue (2020 - 2022)

Historic Cost of Revenue for Immuneering (IMRX) over the last 3 years, with Q3 2022 value amounting to $19343.0.

  • Immuneering's Cost of Revenue fell 9117.11% to $19343.0 in Q3 2022 from the same period last year, while for Jun 2023 it was $19343.0, marking a year-over-year decrease of 9657.09%. This contributed to the annual value of $158122.0 for FY2022, which is 8628.69% down from last year.
  • Immuneering's Cost of Revenue amounted to $19343.0 in Q3 2022, which was down 9117.11% from $47933.0 recorded in Q2 2022.
  • Immuneering's Cost of Revenue's 5-year high stood at $473233.0 during Q4 2020, with a 5-year trough of $19343.0 in Q3 2022.
  • In the last 3 years, Immuneering's Cost of Revenue had a median value of $228075.0 in 2020 and averaged $233649.2.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 3439.56% in 2021, then plummeted by 9117.11% in 2022.
  • Quarter analysis of 3 years shows Immuneering's Cost of Revenue stood at $473233.0 in 2020, then tumbled by 56.42% to $206221.0 in 2021, then plummeted by 90.62% to $19343.0 in 2022.
  • Its last three reported values are $19343.0 in Q3 2022, $47933.0 for Q2 2022, and $90846.0 during Q1 2022.